Related Experiment Videos
Caring for children with drug-resistant tuberculosis: practice-based recommendations
James A Seddon1, Jennifer J Furin, Marianne Gale
1Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Clinical Building, Room 0085, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 19063, Tygerberg, South Africa. jseddon@sun.ac.za
Insights
Managing pediatric drug-resistant tuberculosis (DR-TB) is complex. This guidance synthesizes evidence and expert consensus to support clinicians in treating children with DR-TB effectively.
Area of Science:
- Pediatric Infectious Diseases
- Mycobacterial Research
- Global Health
Background:
- Drug-resistant tuberculosis (DR-TB) management in children presents unique challenges.
- Limited evidence exists for optimal pediatric DR-TB treatment and follow-up protocols.
- Current DR-TB guidelines often inadequately address pediatric-specific needs.
Framework:
- This article provides practical guidance for pediatric DR-TB care.
- It reviews existing literature, research studies, and international guidelines.
- Expert consensus from experienced clinicians informs the recommendations.
Implementation:
- Covers key aspects of pediatric DR-TB management: treatment initiation, regimen selection, and duration.
- Addresses comorbid conditions, monitoring, and adverse event management.
- Emphasizes adherence promotion and infection control within a multidisciplinary approach.
Implications:
- Aims to bridge the evidence gap in pediatric DR-TB care.
- Supports clinicians in diverse settings with varying resources.
- Facilitates improved clinical decision-making and patient outcomes for children with DR-TB.
Abstract:
The management of children with drug-resistant tuberculosis (DR-TB) is challenging, and it is likely that in many places, the roll-out of molecular diagnostic testing will lead to more children being diagnosed. There is a limited evidence base to guide optimal treatment and follow-up in the pediatric population; in existing DR-TB guidelines, the care of children is often relegated to small "special populations" sections. This article seeks to address this gap by providing clinicians with practical advice and guidance. This is achieved through review of the available literature on pediatric DR-TB, including research studies and international guidelines, combined with consensus opinion from a team of experts who have extensive experience in the care of children with DR-TB in a wide variety of contexts and with varying resources. The review covers treatment initiation, regimen design and treatment duration, management of comorbid conditions, treatment monitoring, adverse events, adherence promotion, and infection control, all within a multidisciplinary environment.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Metabolism